ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
DNA Hanger: Surface-Minimized Single-Molecule Immunoassay Platform.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DNA Hanger: Surface-Minimized Single-Molecule Immunoassay Platform.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A novel single-molecule immunoassay platform, termed DNA Hanger, is developed to address the limitations of conventional surface-based assays. By suspending biotinylated λ-phage DNA across microfabricated quartz barriers, this method enables high-specificity protein detection with minimal nonspecific binding. DNA Hanger significantly reduces background signals, achieving nonspecific binding rates as low as one protein per 236 µm of DNA. Quantification of mNeonGreen-tagged human poly(A)-binding protein C1 (mNG-PABP) and single-molecule fluorescence-linked immunosorbent assay (FLISA) of human tumor necrosis factor α (TNF-α) demonstrates the assay's specificity and sensitivity at the single-molecule level, with a detection limit of 0.90 pM in buffer, 38-fold lower than that of conventional FLISA, and 20.6 pM in 70% fetal bovine serum, an 8-fold improvement. DNA Hanger also enables the detection and quantification of endogenous TNF-α in human serum, highlighting its clinical potential. The DNA Hanger assay eliminates the need for surface blocking and simplifies workflow, resulting in completing the immunoassay process within 1 hour. DNA Hanger offers broad applicability for biomolecular interaction studies and clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.